Back to discover
Drug

Kynurenine

In clinical development
Emerging researchEarly-to-mid developmentRising momentum

Also known as (2S)-2-amino-4-(2-aminophenyl)-4-oxobutanoic acid, 3-Anthraniloyl-L-alanine, L-kynurenine.

16
Research papers
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

The Influence of Kynurenine Metabolites on Neurodegenerative Pathologies.

Research2024-01-10International journal of molecular sciences

Tryptophan Metabolism and Gut-Brain Homeostasis.

Research2021-03-15International journal of molecular sciences

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Kynurenine
Aliases & brands
(2S)-2-amino-4-(2-aminophenyl)-4-oxobutanoic acid3-Anthraniloyl-L-alanineL-kynurenine
RxNorm CUI
2710640
ChEMBL ID
CHEMBL498416
UNII
02JW4J5R44

Clinical trials

1 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
1
registered trials across all phases
LATEST COMPLETION 2019
1
Completed
PHASE DISTRIBUTIONn = 1
Phase 11

Recent completions

Trials that read out recently, adding to the completed evidence base.

Research activity

16 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Publications over time
20062024
Most influential
Recent papers
Major research themes8
Kynurenine6Gastrointestinal Microbiome4Indoleamine-Pyrrole 2,3,-Dioxygenase2Nervous System Diseases2Adenocarcinoma of Lung1Alzheimer Disease1Amyloid beta-Peptides1Astrocytes1
Journals, researchers & institutions
Top journals
  • International journal of molecular sciences6
  • Nature communications2
  • British journal of cancer1
  • Cell communication and signaling : CCS1
  • Cells1
  • Cellular & molecular immunology1
Leading researchers
  • Vécsei L3
  • Tanaka M2
  • Zhang L2
  • Andreasson KI1
  • Ay YA1
  • Beach TG1
  • Belladonna ML1
  • Bianchi R1
Leading institutions
free-text, unnormalised
  • Interdisciplinary Excellence Centre2
  • University of Szeged2
  • Albert Szent-Györgyi Clinical Center1
  • Beijing Chest Hospital1
  • Center for Cancer Immunotherapy and Immunobiology1
  • Center for Global Health1

Related diseases

5 conditions

Regulator-approved indications and conditions co-mentioned with this drug across the research literature. Number shows shared papers.

Related drugs

3 matches

Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).

Studied across 5 of the same disease areas as Kynurenine in the shared literature.

5 shared diseases1 shared paper

Studied across 4 of the same disease areas as Kynurenine in the shared literature.

4 shared diseases1 shared paper

Frequently co-studied with Kynurenine in the research literature.

1 shared paper
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials